NativeMed vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
NativeMed
Best for buyers comfortable with sub-$200 promotional compounded GLP-1 pricing who can verify pharmacy partner identity directly with NativeMed support before subscribingStarting at $149/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | NativeMed | Wisp |
|---|---|---|
| Overall Score | ✓7.1/10 | 7.0/10 |
| Starting Price | ✓$149/mo | $225/mo |
| Editorial Rating | ✓3.6 ★ /5 | 3.5 ★ /5 |
| Features | 4 features | ✓6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
NativeMed
Pros
- ✓LegitScript certified per the homepage footer (independently verifiable)
- ✓Promotional pricing publicly displayed: $149/mo semaglutide, $183/mo tirzepatide (sale from $299/$399 regular)
- ✓Async questionnaire workflow with synchronous visit triggered when state law requires it
Cons
- ✗Pharmacy partners are NOT publicly named — material gap for YMYL disclosure (described only as 'USA-based pharmacies' / 'accredited pharmacies')
- ✗States served list is not publicly enumerated
- ✗Pricing displayed as promotional sale price — readers should confirm whether the $149/$183 holds beyond the first month or escalates to the $299/$399 'regular' price
- ✗Trustpilot reviews displayed on homepage — we do NOT cite Trustpilot as a primary source per editorial policy
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
NativeMed edges out Wisp with a higher overall score of 7.1/10 and is particularly strong for buyers comfortable with sub-$200 promotional compounded GLP-1 pricing who can verify pharmacy partner identity directly with NativeMed support before subscribing. Wisp remains a solid alternative, especially if you're looking for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.